🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

164 results for “Janssen” Clear

  1. A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  2. A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms

    Janssen-Cilag International N.V.

    CALR-mutated Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  3. A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  4. A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  5. A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors

    Janssen-Cilag International N.V.

    Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy

    phase 1 other active

    1 trial

  6. A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL

    Janssen-Cilag International N.V.

    relapsed or refractory B‑cell non-Hodgkin lymphomas

    phase 1 other active

    1 trial

  7. A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  8. A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL

    Janssen-Cilag International N.V.

    Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    phase 1 other active

    1 trial

  9. A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  10. A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Participants with Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  11. A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  12. A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Different Types of Co-administered Oral Liquids on the Relative Oral Bioavailability of a JNJ 77242113 Tablet Formulation in Healthy Participants.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  13. A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  14. A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with either JNJ-63723283 (cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 1 other active

    1 trial

  15. A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 1 other active

    1 trial

  16. A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL

    Janssen-Cilag International N.V.

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  17. A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 1 other active

    1 trial

  18. A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  19. A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  20. A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  21. A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants

    Janssen-Cilag International N.V.

    Tuberculosis

    phase 1 other active

    1 trial

  22. A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC

    Janssen-Cilag International N.V.

    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

    phase 1 other active

    1 trial

  23. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole

    Janssen-Cilag International N.V.

    Healthy Adult Participants

    phase 1 other active

    1 trial

  24. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without rabeprazole.

    Janssen-Cilag International N.V.

    Healthy Adult Participants.

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources